Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C

Kyoto University50 enrolled

Overview

The purpose of this study is to evaluate the efficacy and safety of low-dose interferon-alfa-2b plus ribavirin compared to the standard-dose of the same combination in patients with chronic hepatitis C.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hepatitis C, Chronic

Interventions

interferon-alfa-2b and ribavirinDRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of Chronic Hepatitis C. Must be infected with genotype 1b viruses Exclusion Criteria: * Hemoglobin levels\<8.5g/dL, * Platelet counts\<50,000/mm3, * Total polymorphonuclear counts\<1000/mm3 * Pregnancy, * Renal dysfunction,

Locations (4)

Department of Gastroenterology and Hepatology, Kyoto University Hospital

Kyoto, Japan

Kitano Hospital

Osaka, Japan

Osaka Red Cross Hospital

Osaka, Japan

Wakayama Red Cross Hospital

Wakayama, Japan

Outcomes

Primary Outcomes

rate of sustained viral response

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.